360 related articles for article (PubMed ID: 10219891)
1. Hyperthyroidism of Graves' disease: evidence for only unilateral involvement of the thyroid gland in a 31-year-old female patient.
Dimai HP; Ramschak-Schwarzer S; Lax S; Lipp RW; Leb G
J Endocrinol Invest; 1999 Mar; 22(3):215-9. PubMed ID: 10219891
[TBL] [Abstract][Full Text] [Related]
2. Serum immunoglobulin G4 levels and Graves' disease phenotype.
Martin CS; Sirbu AE; Betivoiu MA; Florea S; Barbu CG; Fica SV
Endocrine; 2017 Feb; 55(2):478-484. PubMed ID: 27819113
[TBL] [Abstract][Full Text] [Related]
3. Persistent Graves' hyperthyroidism despite rapid negative conversion of thyroid-stimulating hormone-binding inhibitory immunoglobulin assay results: a case report.
Ohara N; Kaneko M; Kitazawa M; Uemura Y; Minagawa S; Miyakoshi M; Kaneko K; Kamoi K
J Med Case Rep; 2017 Feb; 11(1):32. PubMed ID: 28162094
[TBL] [Abstract][Full Text] [Related]
4. Chronic recurrent stress due to panic disorder does not precipitate Graves' disease.
Chiovato L; Marinò M; Perugi G; Fiore E; Montanelli L; Lapi P; Cavaliere R; Ciampi M; Patronelli A; Placidi G; Placidi GF; Cassano GB; Pinchera A
J Endocrinol Invest; 1998 Dec; 21(11):758-64. PubMed ID: 9972676
[TBL] [Abstract][Full Text] [Related]
5. Thyroid vascularization by color doppler ultrasonography in Graves' disease. Changes related to different phases and to the long-term outcome of the disease.
Baldini M; Castagnone D; Rivolta R; Meroni L; Pappalettera M; Cantalamessa L
Thyroid; 1997 Dec; 7(6):823-8. PubMed ID: 9459623
[TBL] [Abstract][Full Text] [Related]
6. Antithyroid drugs inhibit radioiodine-induced increases in thyroid autoantibodies in hyperthyroid Graves' disease.
Nakazato N; Yoshida K; Mori K; Kiso Y; Sayama N; Tani JI; Nakagawa Y; Ito S
Thyroid; 1999 Aug; 9(8):775-9. PubMed ID: 10482369
[TBL] [Abstract][Full Text] [Related]
7. Fetal Goitrous Hyperthyroidism in a Pregnant Woman with Triiodothyronine-Predominant Graves' Disease.
Washio K; Uenaka M; Tanimura K; Deguchi M; Nishida K; Fujioka K; Yamada H
Kobe J Med Sci; 2021 Feb; 66(4):E153-E158. PubMed ID: 33994519
[TBL] [Abstract][Full Text] [Related]
8. Two cases of Graves' disease with presentation of unilateral diffuse uptake of radioisotopes.
Sakata S; Fuwa Y; Goto S; Fukui M; Yuasa H; Takuno H; Sarui H; Matsui I; Ogawa T; Sasano N
J Endocrinol Invest; 1993 Dec; 16(11):903-7. PubMed ID: 8144868
[TBL] [Abstract][Full Text] [Related]
9. Graves' disease in a mediastinal mass presenting after total thyroidectomy for nontoxic multinodular goiter: a case report.
Cunha FM; Rodrigues E; Oliveira J; Saavedra A; Vinhas LS; Carvalho D
J Med Case Rep; 2016 Mar; 10():70. PubMed ID: 27029843
[TBL] [Abstract][Full Text] [Related]
10. Effect of thyroxine administration on serum thyrotropin receptor antibody and thyroglobulin levels in patients with Graves' hyperthyroidism during antithyroid drug therapy.
Kuo SW; Huang WS; Hu CA; Liao WK; Fung TC; Wu SY
Eur J Endocrinol; 1994 Aug; 131(2):125-30. PubMed ID: 8075781
[TBL] [Abstract][Full Text] [Related]
11. Appearance of anti TSH-receptor antibodies and clinical Graves' disease after radioiodine therapy for hyperfunctioning thyroid adenoma.
Regalbuto C; Salamone S; Scollo C; Vigneri R; Pezzino V
J Endocrinol Invest; 1999 Feb; 22(2):147-50. PubMed ID: 10195384
[TBL] [Abstract][Full Text] [Related]
12. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
Hashizume K; Ichikawa K; Sakurai A; Suzuki S; Takeda T; Kobayashi M; Miyamoto T; Arai M; Nagasawa T
N Engl J Med; 1991 Apr; 324(14):947-53. PubMed ID: 1900575
[TBL] [Abstract][Full Text] [Related]
13. Valuable predictive features of relapse of Graves' disease after antithyroid drug treatment.
Liu X; Shi B; Li H
Ann Endocrinol (Paris); 2015 Dec; 76(6):679-83. PubMed ID: 26514949
[TBL] [Abstract][Full Text] [Related]
14. Graves' disease: diagnostic and therapeutic challenges (multimedia activity).
Kahaly GJ; Grebe SK; Lupo MA; McDonald N; Sipos JA
Am J Med; 2011 Jun; 124(6):S2-3. PubMed ID: 21605717
[TBL] [Abstract][Full Text] [Related]
15. A patient-specific treatment model for Graves' hyperthyroidism.
Pandiyan B; Merrill SJ; Di Bari F; Antonelli A; Benvenga S
Theor Biol Med Model; 2018 Jan; 15(1):1. PubMed ID: 29310665
[TBL] [Abstract][Full Text] [Related]
16. Enhanced thyroid iodine metabolism in patients with triiodothyronine-predominant Graves' disease.
Takamatsu J; Hosoya T; Naito N; Yoshimura H; Kohno Y; Tarutani O; Kuma K; Sakane S; Takeda K; Mozai T
J Clin Endocrinol Metab; 1988 Jan; 66(1):147-52. PubMed ID: 3335601
[TBL] [Abstract][Full Text] [Related]
17. Changes in thyroid volume during antithyroid drug therapy for Graves' disease and its relationship to TSH receptor antibodies, TSH and thyroglobulin.
Yamaguchi Y; Inukai T; Iwashita A; Nishino M; Yamaguchi T; Shohda Y; Shimomura Y; Ohshima K; Kobayashi S; Kobayashi I
Acta Endocrinol (Copenh); 1990 Oct; 123(4):411-5. PubMed ID: 1978459
[TBL] [Abstract][Full Text] [Related]
18. Effect of antithyroid drugs on the occurrence of antibodies against type 2 deiodinase (DIO2), which are involved in hyperthyroid Graves' disease influencing the therapeutic efficacy.
Molnár I; Szentmiklósi JA; Gesztelyi R; Somogyiné-Vári É
Clin Exp Med; 2019 May; 19(2):245-254. PubMed ID: 30610492
[TBL] [Abstract][Full Text] [Related]
19. Influence of thyroid volume on the effect of methimazole in Japanese subjects with mild Graves' disease.
Kimura T; Matsuki M; Kaneto H; Mune T; Kaku K
Eur J Intern Med; 2016 Dec; 36():e31-e32. PubMed ID: 27601286
[No Abstract] [Full Text] [Related]
20. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
Choo YK; Yoo WS; Kim DW; Chung HK
Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
